Open-Label, Non Randomized Phase 2 Study With Safety Run-In

NCT ID: NCT02249429

Last Updated: 2019-09-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-31
• Study Completion Date: 2018-09-11

Brief Summary

The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or refractory lymphomas.

Detailed Description

Open-label, non-randomized, multicentre phase 2 study with a safety run-in evaluating efficacy and safety of bimiralisib (PQR309) in patients with relapsed or refractory lymphoma.

The maximum tolerated dose (MTD) of bimiralisib in patients with advanced solid tumors was defined as 80 mg once daily given continuously (q.d. schedule) in a previous phase 1 study. The safety run-in of this study will follow a modified 3 + 3 design to evaluate the safety of 60 and 80 mg bimiralisib in patients with relapsed or refractory lymphoma administered p.o. once daily during a DLT (dose-limiting toxicity) period of 28 days.

In the safety run-in, three patients will be treated at 60 mg bimiralisib for 28 days. Enrollment and treatment of all three patients may occur simultaneously as 80 mg bimiralisib p.o. qd was established as the MTD in solid tumors. Unless a DLT is observed in any of the three patients during the first 28 days of treatment, the investigators and the sponsor will decide to escalate the dose to 80 mg. Intermittent dosing schedules may be evaluated if, based on the overall evaluation of all the clinical and PK (pharmacokinetic) data from this and other studies with bimiralisib, data emerge during step 1 of the phase 2 expansion in this study, indicating that daily dosing of bimiralisib is not adequately tolerated or inefficacious.

Conditions

Lymphoma, Malignant

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

bimiralisib (PQR309)

Group Type: EXPERIMENTAL

bimiralisib

Intervention Type: DRUG

60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.

Interventions

bimiralisib

60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.

Intervention Type: DRUG

Other Intervention Names

PQR309; PI3K Inhibitor (phosphatidylinositol 3-kinase)

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed diagnosis* of relapsed or refractory lymphoma, received at least two prior lines of therapy including immuno-chemotherapy. Patients with relapsed Chronic Lymphoid Leukemia (CLL) are eligible if they have received one or more prior lines of any approved standard therapy. * archival biopsies may be used if obtained up to a year prior to enrollment; re-biopsy is strongly recommended if last biopsy was obtained more than a year ago.

2. Only for patients in the Phase 2 part: At least one measurable nodal or extra-nodal lesion defined as follows: Clearly measurable (i.e. well-defined boundaries) in at least two perpendicular dimensions on imaging scan with > 1.5 cm in longest transverse diameter.

3. Age ≥ 18 years

4. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1 (See Appendix 2).

5. Adequate organ system functions defined as:

1. Absolute neutrophil count (ANC) ≥1.0x109/l

2. Platelets ≥ 75x109/l

3. Haemoglobin ≥ 85g/L

4. Adequate hepatic function, defined as Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) and Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN (or ALT/AST ≤ 5 times ULN in patients with liver involvement)

5. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN

6. Fasting glucose < 7.0 mmol/L; Glycated haemoglobin (HbA1c) < 6.4%

6. Ability and willingness to swallow and retain oral medication.

7. Willingness and ability to comply with the trial procedures

8. Female and male patients with reproductive potential must agree to use effective contraception from screening until 90 days after discontinuation of PQR309

9. Signed informed consent

Exclusion Criteria

Any of the following conditions precludes enrollment of a patient:

1. Immunosuppression due to:

• Allogeneic hematopoietic stem cell transplant (HSCT)
• Any immune-suppressive therapy within 4 weeks prior to trial treatment start
• Known HIV infection

2. Autologous stem cell transplant within 3 months prior to trial treatment start.

3. Concomitant anticancer therapy (e.g. chemotherapy, radiotherapy, hormonal therapy, immunotherapy, biological response modifier, signal transduction inhibitors).

4. Concomitant treatment with medicinal products that increase the pH (reduce acidity) of the upper gastrointestinal tract, including, but not limited to, proton-pump inhibitors (e.g. omeprazole), H2-antagonists (e.g. ranitidine) and antacids. Patients may be enrolled in the study after a wash-out period sufficient to terminate their effect.

5. Use of any investigational drug within 21 days prior to trial treatment start.

6. Patients who experienced National Cancer Institute (NCI) Common Terminology Criteria For Adverse Events (CTCAE) ≥ Grade 3 on PI3K/mTOR inhibitors

7. Any major surgery, chemotherapy or immunotherapy within 21 days prior to trial treatment start.

8. Symptomatic or progressing Central nervous system (CNS) involvement. Exception: Patients with meningeal involvement can be included upon discussion between the sponsor and the investigator.

9. Persisting toxicities NCI CTCAE ≥2 related to prior anticancer therapy

10. Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.

11. Severe/unstable angina, myocardial infarction or coronary artery bypass within the last 3 years prior to trial treatment start, symptomatic congestive heart failure New York Heart Association (NYHA) Class 3 or 4, hypertension BP>150/100mmHg

12. A serious active infection at the time of treatment, or another serious underlying medical condition that could impair the ability of the patient to receive treatment.

13. Lack of appropriate contraceptive measures (male and female)

14. Pregnant or lactating women

15. Known HIV infection

16. Significant medical conditions which could jeopardize compliance with the protocol.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University College London Hospitals

OTHER

Sponsor Role: collaborator

Churchill Hospital

OTHER

Sponsor Role: collaborator

Royal Marsden NHS Foundation Trust

OTHER

Sponsor Role: collaborator

University of Haifa

OTHER

Sponsor Role: collaborator

Weill Medical College of Cornell University

OTHER

Sponsor Role: collaborator

Institut Curie

OTHER

Sponsor Role: collaborator

University Clinical Center, Sarajevo

UNKNOWN

Sponsor Role: collaborator

Clinical Center Kragujevac

OTHER

Sponsor Role: collaborator

Clinical Center Nis, Nis

UNKNOWN

Sponsor Role: collaborator

Institute for Oncology and Radiology Serbia, Belgrade

UNKNOWN

Sponsor Role: collaborator

University Clinical Centre of Republic of Srpska

OTHER

Sponsor Role: collaborator

PIQUR Therapeutics AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rakesh Popat

Role: PRINCIPAL_INVESTIGATOR

Univeristy College London

David Cunningham

Role: PRINCIPAL_INVESTIGATOR

Royal Marsden NHS Foundation Trust

Paul Fields

Role: PRINCIPAL_INVESTIGATOR

Guy's Hospital

Graham Collins

Role: PRINCIPAL_INVESTIGATOR

Churchill Hospital

Netanel Horowitz

Role: PRINCIPAL_INVESTIGATOR

University of Haifa

Giulino Roth

Role: PRINCIPAL_INVESTIGATOR

Weill Cornell Medicine New York

Carole Soussain

Role: PRINCIPAL_INVESTIGATOR

Curie Institute

Sinisa Radulovic

Role: PRINCIPAL_INVESTIGATOR

Institute for Oncology and Radiology Serbia

Ivan Tijanic

Role: PRINCIPAL_INVESTIGATOR

Clinical Center Nis

Nebojsa Andjelkovic

Role: PRINCIPAL_INVESTIGATOR

Clinical Center Kragujevac

Sabrina Kurtovic

Role: PRINCIPAL_INVESTIGATOR

University Clinical Center, Sarajevo

Danijela Mandic

Role: PRINCIPAL_INVESTIGATOR

University Clinical Centre of Republic of Srpska

Locations

Weill Cornell Medicine

New York, New York, United States

University Clinical Center Republic of Srpska

Banja Luka, , Bosnia and Herzegovina

University Clinical Center Sarajevo

Sarajevo, , Bosnia and Herzegovina

Insitute Curie

Saint-Cloud, Paris, France

Univeristy Hospital Haifa

Haifa, , Israel

Institute for Oncology and radiology of Serbia

Belgrade, , Serbia

Clinical Center Kragujevac

Kragujevac, , Serbia

Clinical Center Nis

Niš, , Serbia

Guy's Hospital

London, , United Kingdom

Royal Marsden NHS Foundation Trust

London, , United Kingdom

University College Hospital London

London, , United Kingdom

Churchill Hospital

Oxford, , United Kingdom

Countries

United States; Bosnia and Herzegovina; France; Israel; Serbia; United Kingdom

Other Identifiers

PQR309-002

Identifier Type: -

Identifier Source: org_study_id